Definium Therapeutics, Inc. (DFTX) Stock Analysis — Probabli.AI
AI-powered analysis for DFTX (Definium Therapeutics, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $36.18 · Market cap: $2.7B · AI outlook: Bullish
Definium Therapeutics, Inc. (DFTX) is positioned for substantial short-term growth with promising phase 3 trial results, a significant collaboration with a pharma giant, and a strong 'strong buy' analyst consensus pointing towards potential stock appreciation. Despite facing challenges like earnings surprises and patent disputes, its innovative drug pipeline and strategic partnerships create…
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 25% · Bear 20%
- 1-year price estimates — P10: $28 / P50: $55 / P90: $70
- Definium Therapeutics has shown potential for rapid short-term appreciation due to significant positive news, including promising phase 3 results and a major collaboration deal. Despite a history of missing earnings…
5-Year Outlook
- Bull 60% · Neutral 20% · Bear 20%
- 5-year price estimates — P10: $40 / P50: $95 / P90: $180
SWOT Highlights
- Strength: Promising phase 3 trial results
- Strength: Strong collaborations with major pharma companies
- Risk: Consistent earnings misses
- Risk: Negative average EPS surprise
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
15 Wall Street analysts rate DFTX a STRONG BUY with a mean price target of $48.54.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
DFTX forecast details · DFTX sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.